A1 Journal article (refereed)
Muscle NAD+ depletion and Serpina3n as molecular determinants of murine cancer cachexia : the effects of blocking myostatin and activins (2020)

Hulmi, J., Penna, F., Pöllänen, N., Nissinen, T., Hentilä, J., Euro, L., Lautaoja, J., Ballarò, R., Soliymani, R., Baumann, M., Ritvos, O., Pirinen, E., & Lalowski, M. (2020). Muscle NAD+ depletion and Serpina3n as molecular determinants of murine cancer cachexia : the effects of blocking myostatin and activins. Molecular Metabolism, 41, 101046. https://doi.org/10.1016/j.molmet.2020.101046

JYU authors or editors

Hulmi, Juha
Nissinen, Tuuli
Hentilä, Jaakko
Lautaoja, Juulia

Publication details

All authors or editors: Hulmi, J.; Penna, F.; Pöllänen, N.; Nissinen, T.; Hentilä, J.; Euro, L.; Lautaoja, J.; Ballarò, R.; Soliymani, R.; Baumann, M.; et al.

Journal or series: Molecular Metabolism

ISSN: 2212-8778

eISSN: 2212-8778

Publication year: 2020

Volume: 41

Pages range: 101046

Publisher: Elsevier

Publication country: Netherlands

Publication language: English

DOI: https://doi.org/10.1016/j.molmet.2020.101046

Publication open access: Openly available

Publication channel open access: Open Access channel

Publication is parallel published (JYX): https://jyx.jyu.fi/handle/123456789/71196

Abstract

Objective Cancer cachexia and muscle loss are associated with increased morbidity and mortality. In preclinical animal models, blocking activin receptor (ACVR) ligands has improved survival and prevented muscle wasting in cancer cachexia without an effect on tumour growth. However, the underlying mechanisms are poorly understood. The present study aimed to identify cancer cachexia and soluble ACVR (sACVR) administration-evoked changes in muscle proteome. Methods Healthy and C26 tumour-bearing (TB) mice were treated with recombinant sACVR. The sACVR or PBS control were administered either prior to the tumour formation or by continued administration before and after tumour formation. Muscles were analysed by quantitative proteomics with further examination of mitochondria and nicotinamide adenine dinucleotide (NAD+) metabolism. To complement the first prophylactic experiment, sACVR (or PBS) was injected as a treatment following tumour cell inoculation. Results Muscle proteomics in TB cachectic mice revealed downregulated signatures for mitochondrial oxidative phosphorylation (OXPHOS) and increased acute phase response (APR). These were accompanied by muscle NAD+ deficiency, alterations in NAD+ biosynthesis including downregulation of nicotinamide riboside kinase 2 (Nrk2), and decreased muscle protein synthesis. The disturbances in NAD+ metabolism and protein synthesis were rescued upon treatment with sACVR. Across the whole proteome and APR in particular, Serpina3n represented the most upregulated protein and the strongest predictor of cachexia. However, the increase in Serpina3n expression associated with increased inflammation rather than decreased muscle mass and/or protein synthesis. Conclusions We present here an evidence implicating disturbed muscle mitochondrial OXPHOS proteome and NAD+ homeostasis in experimental cancer cachexia. Treatment of tumour-bearing mice with a blocker of activin receptor ligands restores depleted muscle NAD+ and Nrk2 as well as decreased muscle protein synthesis. These results point out putative new treatment therapies for cachexia. Our results also reveal that although acute phase protein Serpina3n may serve as a predictor of cachexia, it more likely reflects a condition of elevated inflammation.

Keywords: muscular atrophies; cancerous diseases; muscle cells; metabolism; proteins

Free keywords: cancer cachexia; activin receptor; Nrk2; APR; OXPHOS

Fields of science: